Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where David A. Ashford is active.

Publication


Featured researches published by David A. Ashford.


Emerging Infectious Diseases | 2002

Investigation of bioterrorism-related anthrax, United States, 2001: epidemiologic findings.

Daniel B. Jernigan; Pratima L. Raghunathan; Beth P. Bell; Ross J. Brechner; Eddy A. Bresnitz; Jay C. Butler; Marty Cetron; Mitch Cohen; Timothy J. Doyle; Marc Fischer; Carolyn M. Greene; Kevin S. Griffith; Jeannette Guarner; James L. Hadler; James A. Hayslett; Richard F. Meyer; Lyle R. Petersen; Michael R. Phillips; Robert W. Pinner; Tanja Popovic; Conrad P. Quinn; Jennita Reefhuis; Dori B. Reissman; Nancy E. Rosenstein; Anne Schuchat; Wun-Ju Shieh; Larry Siegal; David L. Swerdlow; Fred C. Tenover; Marc S. Traeger

In October 2001, the first inhalational anthrax case in the United States since 1976 was identified in a media company worker in Florida. A national investigation was initiated to identify additional cases and determine possible exposures to Bacillus anthracis. Surveillance was enhanced through health-care facilities, laboratories, and other means to identify cases, which were defined as clinically compatible illness with laboratory-confirmed B. anthracis infection. From October 4 to November 20, 2001, 22 cases of anthrax (11 inhalational, 11 cutaneous) were identified; 5 of the inhalational cases were fatal. Twenty (91%) case-patients were either mail handlers or were exposed to worksites where contaminated mail was processed or received. B. anthracis isolates from four powder-containing envelopes, 17 specimens from patients, and 106 environmental samples were indistinguishable by molecular subtyping. Illness and death occurred not only at targeted worksites, but also along the path of mail and in other settings. Continued vigilance for cases is needed among health-care providers and members of the public health and law enforcement communities.


Journal of Clinical Microbiology | 2003

Evaluation of Four Commercially Available Rapid Serologic Tests for Diagnosis of Leptospirosis

Mary D. Bajani; David A. Ashford; Sandra L. Bragg; Christopher W. Woods; Tin Aye; Richard A. Spiegel; Brian D. Plikaytis; Bradley A. Perkins; Maureen Phelan; Paul N. Levett; Robbin S. Weyant

ABSTRACT Four rapid tests for the serologic diagnosis of leptospirosis were evaluated, and the performance of each was compared with that of the current standard, the microscopic agglutination test (MAT). The four rapid tests were a microplate immunoglobulin M (IgM)-enzyme-linked immunosorbent assay (ELISA), an indirect hemagglutination assay (IHA), an IgM dipstick assay (LDS), and an IgM dot-ELISA dipstick test (DST). A panel of 276 sera from 133 cases of leptospirosis from four different geographic locations was tested as well as 642 sera from normal individuals or individuals with other infectious or autoimmune diseases. Acute-phase sera from cases (n = 148) were collected ≤14 days (median = 6.0) after the onset of symptoms, and convalescent-phase sera (n = 128) were collected ≥15 days after onset (median = 29.1). By a traditional method (two-by-two contingency table), the sensitivities for detection of leptospirosis cases were 93.2% by LDS, 92.5% by DST, 86.5% by ELISA, and 79.0% by IHA. Specificity was 98.8% by DST, 97% by ELISA and MAT, 95.8% by IHA, and 89.6% by LDS. With a latent class analysis (LCA) model that included all the rapid tests and the clinical case definition, sensitivity was 95.5% by DST, 94.5% by LDS, 89.9% by ELISA, and 81.1% by IHA. The sensitivity and specificity estimated by the traditional methods were quite close to the LCA estimates. However, LCA allowed estimation of the sensitivity of the MAT (98.2%), which traditional methods do not allow. For acute-phase sera, sensitivity was 52.7% by LDS, 50.0% by DST, 48.7% by MAT and ELISA, and 38.5% by IHA. The sensitivity for convalescent-phase sera was 93.8% by MAT, 84.4% by DST, 83.6% by LDS, 75.0% by ELISA, and 67.2% by IHA. A good overall correlation with the MAT was obtained for each of the assays, with the highest concordance being with the DST (kappa value, 0.85; 95% confidence interval [CI], 0.8 to 0.90). The best correlation was between ELISA and DST (kappa value, 0.86; 95% CI, 0.81 to 0.91). False-positive LDS results were frequent (≥20%) in sera from individuals with Epstein-Barr virus, human immunodeficiency virus, and periodontal disease and from healthy volunteers. The ease of use and significantly high sensitivity and specificity of DST and ELISA make these good choices for diagnostic testing.


Clinical Infectious Diseases | 2002

Outbreak of Leptospirosis among Triathlon Participants and Community Residents in Springfield, Illinois, 1998

Juliette Morgan; Shari L. Bornstein; Adam Karpati; Michael G. Bruce; Carole A. Bolin; Constance C. Austin; Christopher W. Woods; Jairam R. Lingappa; Carl Langkop; Belinda Davis; Donald R. Graham; Mary E. Proctor; David A. Ashford; Mary D. Bajani; Sandra L. Bragg; Kathleen A. Shutt; Bradley A. Perkins; Jordan W. Tappero

We investigated an outbreak of leptospirosis among athletes and community residents after a triathlon was held in Springfield, Illinois. A telephone survey was conducted to collect clinical information and data on possible risk factors, community surveillance was established, and animal specimens and lake water samples were collected to determine the source of the leptospiral contamination. A total of 834 of 876 triathletes were contacted; 98 (12%) reported being ill. Serum samples obtained from 474 athletes were tested; 52 of these samples (11%) tested positive for leptospirosis. Fourteen (6%) of 248 symptomatic community residents tested positive for leptospirosis. Heavy rains that preceded the triathlon are likely to have increased leptospiral contamination of Lake Springfield. Among athletes, ingestion of 1 or more swallows of lake water was a predominant risk factor for illness. This is the largest outbreak of leptospirosis that has been reported in the United States. Health care providers and occupational and recreational users of bodies of freshwater in the United States should be aware of the risk of contracting leptospirosis, particularly after heavy rains.


Emerging Infectious Diseases | 2003

Leptospirosis in “Eco-Challenge” Athletes, Malaysian Borneo, 2000

James J. Sejvar; Elizabeth Bancroft; Kevin Winthrop; Julie A. Bettinger; Mary D. Bajani; Sandra L. Bragg; Kathleen A. Shutt; Robyn M. Kaiser; Nina Marano; Tanja Popovic; Jordan W. Tappero; David A. Ashford; Laurene Mascola; Duc J. Vugia; Bradley A. Perkins; Nancy E. Rosenstein

Adventure travel is becoming more popular, increasing the likelihood of contact with unusual pathogens. We investigated an outbreak of leptospirosis in “Eco-Challenge” multisport race athletes to determine illness etiology and implement public health measures. Of 304 athletes, we contacted 189 (62%) from the United States and 26 other countries. Eighty (42%) athletes met our case definition. Twenty-nine (36%) case-patients were hospitalized; none died. Logistic regression showed swimming in the Segama River (relative risk [RR]=2.0; 95% confidence interval [CI]=1.3 to 3.1) to be an independent risk factor. Twenty-six (68%) of 38 case-patients tested positive for leptospiral antibodies. Taking doxycycline before or during the race was protective (RR=0.4, 95% CI=0.2 to 1.2) for the 20 athletes who reported using it. Increased adventure travel may lead to more frequent exposure to leptospires, and preexposure chemoprophylaxis for leptospirosis (200 mg oral doxycycline/week) may decrease illness risk. Efforts are needed to inform adventure travel participants of unique infections such as leptospirosis.


American Journal of Pathology | 2003

Pathology and Pathogenesis of Bioterrorism-Related Inhalational Anthrax

Jeannette Guarner; John A. Jernigan; Wun-Ju Shieh; Kathleen M. Tatti; Lisa M. Flannagan; David S. Stephens; Tanja Popovic; David A. Ashford; Bradley A. Perkins; Sherif R. Zaki

During October and November 2001, public health authorities investigated 11 patients with inhalational anthrax related to a bioterrorism attack in the United States. Formalin-fixed samples from 8 patients were available for pathological and immunohistochemical (IHC) study using monoclonal antibodies against the Bacillus anthracis cell wall and capsule. Prominent serosanguinous pleural effusions and hemorrhagic mediastinitis were found in 5 patients who died. Pulmonary infiltrates seen on chest radiographs corresponded to intraalveolar edema and hyaline membranes. IHC assays demonstrated abundant intra- and extracellular bacilli, bacillary fragments, and granular antigen-staining in mediastinal lymph nodes, surrounding soft tissues, and pleura. IHC staining in lung, liver, spleen, and intestine was present primarily inside blood vessels and sinusoids. Grams staining of tissues was not consistently positive. In 3 surviving patients, IHC of pleural samples demonstrated abundant granular antigen-staining and rare bacilli while transbronchial biopsies showed granular antigen-staining in interstitial cells. In surviving patients, bacilli were not observed with grams stains. Pathological and IHC studies of patients who died of bioterrorism-related inhalational anthrax confirmed the route of infection. IHC was indispensable for diagnosis of surviving anthrax cases. The presence of B. anthracis antigens in the pleurae could explain the prominent and persistent hemorrhagic pleural effusions.


Emerging Infectious Diseases | 2002

Specific, sensitive, and quantitative enzyme-linked immunosorbent assay for human immunoglobulin G antibodies to anthrax toxin protective antigen.

Conrad P. Quinn; Vera A. Semenova; Cheryl M. Elie; Sandra Romero-Steiner; Carolyn M. Greene; Han Li; Karen Stamey; Evelene Steward-Clark; Daniel S. Schmidt; Elizabeth A. Mothershed; Janet M. Pruckler; Stephanie B. Schwartz; Robert F. Benson; Leta O. Helsel; Patricia Holder; Scott E. Johnson; Molly E. Kellum; Trudy O. Messmer; W. Lanier Thacker; Lilah Besser; Brian D. Plikaytis; Thomas H. Taylor; Alison E. Freeman; Kelly J. Wallace; Peter M. Dull; Jim Sejvar; Erica Bruce; Rosa Moreno; Anne Schuchat; Jairam R. Lingappa

The bioterrorism-associated human anthrax epidemic in the fall of 2001 highlighted the need for a sensitive, reproducible, and specific laboratory test for the confirmatory diagnosis of human anthrax. The Centers for Disease Control and Prevention developed, optimized, and rapidly qualified an enzyme-linked immunosorbent assay (ELISA) for immunoglobulin G (IgG) antibodies to Bacillus anthracis protective antigen (PA) in human serum. The qualified ELISA had a minimum detection limit of 0.06 µg/mL, a reliable lower limit of detection of 0.09 µg/mL, and a lower limit of quantification in undiluted serum specimens of 3.0 µg/mL anti-PA IgG. The diagnostic sensitivity of the assay was 97.8%, and the diagnostic specificity was 94.2%. A competitive inhibition anti-PA IgG ELISA was also developed to enhance diagnostic specificity to 100%. The anti-PA ELISAs proved valuable for the confirmation of cases of cutaneous and inhalational anthrax and evaluation of patients in whom the diagnosis of anthrax was being considered.


Emerging Infectious Diseases | 2003

Inactivation of Bacillus anthracis Spores

Ellen A. Spotts Whitney; Mark E. Beatty; Thomas H. Taylor; Robbin S. Weyant; Jeremy Sobel; Matthew J. Arduino; David A. Ashford

After the intentional release of Bacillus anthracis through the U.S. Postal Service in the fall of 2001, many environments were contaminated with B. anthracis spores, and frequent inquiries were made regarding the science of destroying these spores. We conducted a survey of the literature that had potential application to the inactivation of B. anthracis spores. This article provides a tabular summary of the results.


Emerging Infectious Diseases | 2003

Histopathologic features of Mycobacterium ulcerans infection.

Jeannette Guarner; Jeanine Bartlett; Ellen A. Spotts Whitney; Pratima L. Raghunathan; Ymkje Stienstra; Kwame Asamoa; Samuel Etuaful; Erasmus Klutse; Eric Quarshie; Tjip S. van der Werf; Winette T. A. van der Graaf; C. Harold King; David A. Ashford

Because of the emergence of Buruli ulcer disease, the World Health Organization launched a Global Buruli Ulcer Initiative in 1998. This indolent skin infection is caused by Mycobacterium ulcerans. During a study of risk factors for the disease in Ghana, adequate excisional skin-biopsy specimens were obtained from 124 clinically suspicious lesions. Buruli ulcer disease was diagnosed in 78 lesions since acid-fast bacilli (AFB) were found by histopathologic examination. Lesions with other diagnoses included filariasis (3 cases), zygomycosis (2 cases), ulcerative squamous cell carcinomas (2 cases), keratin cyst (1 case), and lymph node (1 case). Thirty-seven specimens that did not show AFB were considered suspected Buruli ulcer disease cases. Necrosis of subcutaneous tissues and dermal collagen were found more frequently in AFB-positive specimens compared with specimens from suspected case-patients (p<0.001). Defining histologic criteria for a diagnosis of Buruli ulcer disease is of clinical and public health importance since it would allow earlier treatment, leading to less deforming sequelae.


Clinical Infectious Diseases | 2005

Risk factors for Buruli ulcer disease (Mycobacterium ulcerans infection) : Results from a case-control study in Ghana

Pratima L. Raghunathan; Ellen A. Whitney; Kwame Asamoa; Ymkje Stienstra; Thomas H. Taylor; George K. Amofah; David Ofori-Adjei; Karen M. Dobos; Jeannette Guarner; Stacey Martin; Sonal Pathak; Erasmus Klutse; Samuel Etuaful; Winette T. A. van der Graaf; Tjip S. van der Werf; Ch King; Jordan W. Tappero; David A. Ashford

BACKGROUND Morbidity due to Buruli ulcer disease (BUD), a cutaneous infection caused by Mycobacterium ulcerans, has been increasingly recognized in rural West Africa. The source and mode of transmission remain unknown. METHODS To identify BUD risk factors, we conducted a case-control study in 3 BUD-endemic districts in Ghana. We enrolled case patients with clinically diagnosed BUD and obtained skin biopsy specimens. M. ulcerans infection was confirmed by at least 1 of the following diagnostic methods: histopathologic analysis, culture, polymerase chain reaction, and Ziehl-Neelsen staining of a lesion smear. We compared characteristics of case patients with confirmed BUD with those of age- and community-matched control subjects using conditional logistic regression analysis. RESULTS Among 121 case patients with confirmed BUD, leg lesions (49%) or arm lesions (36%) were common. Male case patients were significantly more likely than female case patients to have lesions on the trunk (25% vs. 6%; P = .009). Multivariable modeling among 116 matched case-control pairs identified wading in a river as a risk factor for BUD (odds ratio [OR], 2.69; 95% confidence interval [CI], 1.27-5.68; P = .0096). Wearing a shirt while farming (OR, 0.27; 95% CI, 0.11-0.70; P = .0071), sharing indoor living space with livestock (OR, 0.36; 95% CI, 0.15-0.86; P = .022), and bathing with toilet soap (OR, 0.41; 95% CI, 0.19-0.90; P = .026) appeared to be protective. BUD was not significantly associated with penetrating injuries (P = .14), insect bites near water bodies (P = .84), bacille Calmette-Guerin vaccination (P = .33), or human immunodeficiency virus infection (P = .99). CONCLUSIONS BUD is an environmentally acquired infection strongly associated with exposure to river areas. Exposed skin may facilitate transmission. Until transmission is better defined, control strategies in BUD-endemic areas could include covering exposed skin.


Clinical Infectious Diseases | 2002

Leptospirosis, Water Sports, and Chemoprophylaxis

David A. Haake; Manjula Dundoo; Rumi Cader; Bernard M. Kubak; Rudy A. Hartskeerl; James J. Sejvar; David A. Ashford

Recreational activities, such as water sports and adventure travel, are emerging as an important risk factor for leptospirosis, a potentially fatal zoonosis. We report the clinical course of 2 patients who acquired leptospirosis through participation in water sports. Physicians caring for patients who participate in adventure travel involving water sports should be familiar with the risk factors for and diagnosis, prevention, and treatment of leptospirosis.

Collaboration


Dive into the David A. Ashford's collaboration.

Top Co-Authors

Avatar

Jordan W. Tappero

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Bradley A. Perkins

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Ellen A. Spotts Whitney

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Pratima L. Raghunathan

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Sandra L. Bragg

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Robbin S. Weyant

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Tanja Popovic

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Thomas H. Taylor

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Ymkje Stienstra

University Medical Center Groningen

View shared research outputs
Researchain Logo
Decentralizing Knowledge